TY - JOUR
T1 - Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools
T2 - is there room for improvement?
AU - Palma, Mariana L.
AU - Zamith-Miranda, Daniel
AU - Martins, Flaviano S.
AU - Bozza, Fernando A.
AU - Nimrichter, Leonardo
AU - Montero-Lomeli, Mônica
AU - Marques, Ernesto T.A.
AU - Douradinha, Bruno
N1 - Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.
PY - 2015/8/27
Y1 - 2015/8/27
N2 - The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application.
AB - The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application.
KW - Expression of heterologous proteins
KW - Mechanisms of action
KW - Probiotics
KW - Saccharomyces cerevisiae
KW - Saccharomyces cerevisiae var boulardii
UR - http://www.scopus.com/inward/record.url?scp=84937842255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937842255&partnerID=8YFLogxK
U2 - 10.1007/s00253-015-6776-x
DO - 10.1007/s00253-015-6776-x
M3 - Review article
C2 - 26142388
AN - SCOPUS:84937842255
SN - 0175-7598
VL - 99
SP - 6563
EP - 6570
JO - Applied Microbiology and Biotechnology
JF - Applied Microbiology and Biotechnology
IS - 16
ER -
